Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: A randomised, double-blind phase II study

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 4, 2007, Pages 286-291

  Lazar, L ^a,b   Ofan, R ^a   Weintrob, N ^a,b   Avron, A ^c   Tamir, M ^c   Elias, D ^c   Phillip, Moshe ^a,b   Josefsberg, Z ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c DeveloGen Israel Ltd   (Israel)

Author keywords

C peptide; Children; DiaPep277; Hsp60; Type 1 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; DIAPEP277; HEAT SHOCK PROTEIN 60; HEMOGLOBIN A1C; INSULIN; INTRALIPID; MANNITOL; PEPTIDE P277; PLACEBO; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACUTE GASTROENTERITIS; ADOLESCENT; ARTICLE; CELL DESTRUCTION; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC REGULATION; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROENTERITIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; PEPTIDES; TREATMENT OUTCOME;

EID: 34249820806     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.711     Document Type: Article

References (22)

1. Eisenbarth GS. Type 1 diabetes mellitus, a chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368.
2. Wallensteen M, Dahlquist G, Persson B, et al. Factors influencing the magnitude, duration, and rate of fall of β-cell function in type 1 diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988; 31: 664-669.
3. The DCCT Research Group. Effects of age, duration and treatment of insulin dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
4. Sjoberg S, Gunnarsson R, Gjotterberg M, et al. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 208-213.
5. Steffes MW, Sibley S, Jackson M, Thomas W. β-Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
7. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985; 2: 271-276.
8. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319: 599-604.
9. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes of recent onset. Science 1984; 223: 1362-1367.
10. Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39: 1264-1272.
11. Lipton R, LaPorte RE, Becker DJ, et al. Cyclosporin therapy for prevention and cure of IDDM; epidemiological perspective of benefits and risks. Diabetes Care 1990; 13: 776-784.
12. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
13. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
14. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Exp Anim 1980; 29: 1-13.
15. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994; 343: 704-706.
16. Elias D, Meilin A, Ablamunits V, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997; 46: 758-764.
17. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358: 1749-1753.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2000; 23: S4.
19. Grubin CE, Daniels T, Toivola B, et al. A novel radioligand-binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetolgia 1994; 37: 344-350.
20. Clarson C, Daneman D, Drash AL, et al. Residual B-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve. Diabetes Care 1987; 10: 33-38.
21. Leslie RD, Delli Castelli M. Age dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004; 53: 3033-3040.
22. Abulafia-Lapid R, Gillis D, Yosef O, et al. T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun 2003; 20: 313-321.